Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Fitness and Spironolactone on Vascular Dysfunction in Type 1 Diabetes
NCT03174288Phase 2Completed
- Sponsor
- University of Virginia
- Start
- Aug 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of spironolactone in vascular dysfunction (3 arms), sponsored by University of Virginia. Primary endpoint: Augmentation Index at 24 weeks. Started Aug 2015; status: completed.
02
Drugs
spironolactone
03
Conditions
vascular dysfunction
Beyond the preview
Go deeper on NCT03174288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174288.